Financial Perspectives Inc Grows Stock Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Financial Perspectives Inc raised its position in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 80.0% during the fourth quarter, HoldingsChannel reports. The firm owned 6,750 shares of the company’s stock after purchasing an additional 3,000 shares during the period. Financial Perspectives Inc’s holdings in Werewolf Therapeutics were worth $26,000 at the end of the most recent reporting period.

Werewolf Therapeutics Stock Up 5.7 %

Shares of NASDAQ HOWL traded up $0.35 during mid-day trading on Tuesday, hitting $6.44. 393,885 shares of the stock traded hands, compared to its average volume of 246,488. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics, Inc. has a 52 week low of $1.57 and a 52 week high of $8.19. The stock has a fifty day moving average price of $6.26 and a 200-day moving average price of $4.42.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.10. The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.75 million. Werewolf Therapeutics had a negative return on equity of 32.25% and a negative net margin of 187.37%. As a group, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.38 EPS for the current year.

Analysts Set New Price Targets

Separately, JMP Securities assumed coverage on shares of Werewolf Therapeutics in a report on Wednesday, April 3rd. They issued a “mkt outperform” rating and a $12.00 price objective for the company.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.